TidLira 30mg Tirzepatide 30 | Pre-Filled Pen
Lira Pharma TidLira 30mg is a multi-dose pre-filled injection pen labelled as containing 30mg of tirzepatide. Tirzepatide is a dual GIP and GLP-1 receptor agonist that acts on hormone pathways involved in appetite, glucose regulation and energy intake.
Tirzepatide has established clinical uses for type 2 diabetes and chronic weight management, depending on the approved product and indication. Its effects on appetite and food intake can contribute to significant reductions in body weight.
What Lira Pharma TidLira 30mg Is Used For
Tirzepatide is associated with:
Supporting weight loss and long-term weight management
Helping to reduce appetite and overall calorie intake
Increasing feelings of fullness and satiety
Supporting improved blood-glucose control
Improving the body's glucose-dependent insulin response
Supporting improvements in certain metabolic health markers
Tirzepatide has been shown to reduce food intake and body weight while improving fasting and post-meal glucose concentrations.
How Lira Pharma TidLira 30mg Works
Tirzepatide simultaneously activates two important metabolic hormone receptors:
GIP receptors – involved in glucose-dependent insulin secretion and metabolic regulation
GLP-1 receptors – involved in appetite regulation, satiety and glucose-dependent insulin secretion
Through this combined action, tirzepatide can increase insulin secretion when glucose is elevated, reduce glucagon concentrations, decrease food intake and support body-weight reduction.
How to Use Lira Pharma TidLira 30mg
TidLira is supplied as a pre-filled multi-dose pen, meaning no separate vial reconstitution is required.
Tirzepatide is generally administered once weekly, preferably on the same day each week. Dose escalation is commonly used to improve gastrointestinal tolerability.
Administration Route: Subcutaneous injection.
Dosage Information
Total labelled content per pen: 30mg Tirzepatide
The TidLira packaging uses a click-based dosing system. Because pen concentrations and delivery mechanisms can vary between manufacturers, dosing should be based on the verified concentration and instructions for the specific product rather than assuming click counts are interchangeable between different pens.
Approved tirzepatide products use gradual dose escalation, and the appropriate dose should be determined according to individual response, tolerability and professional medical guidance.
Always use a new sterile needle where applicable and never share an injection pen with another person, even if the needle is changed.
Possible Side Effects
Tirzepatide is commonly associated with gastrointestinal side effects, particularly when treatment begins or the dose is increased.
Common
Nausea
Diarrhoea
Decreased appetite
Vomiting
Constipation
Indigestion
Abdominal discomfort or pain
